Product Development
EDE Pharmaceuticals product development focuses on product that have reached Phase I, II. EDE has a diversified portfolio of products in infectious diseases, oncology, neurological disorder (CNS) and pain management, that have the potential for accelerated or fast track approvals. In the near-term EDE Pharmaceuticals will focus on products in the areas of infectious disease and neurological diseases.
A favorable regulatory environment for drugs to treat life-threatening and serious diseases will allows EDE to bring products relatively fast in the market at a fraction of the cost of traditional pharmaceutical R&D. Product Identification and Selection EDE Pharmaceuticals business model includes an authoritative Scientific & Portfolio Management Board made of industry's prominent scientific leaders in EDE's focus therapeutic areas. Their responsibility is to evaluate score of potential drug targets according to a filter and sieving process based on their established scientific soundness, pharmacology and toxicology, the time and cost for their development and manufacturability, and the availability of a fast-track regulatory path. |
Clinical Research DevelopmentThe Enhanced Innovative Virtual Drug Development Network (VDD-EIN) business model provides EDE with unparalleled flexibility, and effectiveness which allow us to undertake multiple products through development and design project teams according to the particular needs of the company, by integrating the services provided with a team of specialized vendors. Products will be developed from Phase II to Phase III trials by the drug development partnerships. Products are out licensed to third parties following completion of Phase II trial or Phase III post FDA approval depending on the drug under development. EDE takes its products to patients through distribution partnerships with leading sales and marketing partners.
Product Pipeline Drugs in Development for the following diseases: 
|
|
|
Site powered by Weebly. Managed by Hostmonster